Ten-year APHINITY data show Roche’s Perjeta-based regimen reduced risk of death by 17%

Swiss pharma giant Roche (ROG: SIX), the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support Unit and Frontier Science Foundation, today announced statistically-significant final overall survival (OS) results from the phase III APHINITY study in people with human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer.

After ten years, the risk of death was reduced by 17% for people treated with Perjeta (pertuzumab), Herceptin (trastuzumab) and chemotherapy (the Perjeta-based regimen) for a year as post-surgery (adjuvant) treatment, compared with individuals who received Herceptin, chemotherapy, and placebo.

“Early treatment of breast cancer can provide substantial patient benefit and also increases the chance for cure. For people with early-stage HER2-positive disease, the APHINITY results validate the sustained benefits of the Perjeta-based regimen,” said Dr Levi Garraway, Roche’s chief medical officer and head of global product development. “These long-term data reinforce the regimen’s value as a well-established standard-of-care treatment in the curative setting,” he added.